Spots Global Cancer Trial Database for npc
Every month we try and update this database with for npc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer | NCT00078494 | Nasopharyngeal ... | EBV-LMP-2 | - | National Institutes of Health Clinical Center (CC) | |
| Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma | NCT03919552 | Cisplatin Carboplatin NPC | Docetaxel,Carbo... Docetaxel,Cispl... Carboplatin-bas... Cisplatin-based... | 18 Years - 64 Years | Nanfang Hospital, Southern Medical University | |
| Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma (NPC) | NCT00817583 | Nasopharyngeal ... | docetaxel, cisp... 3D-CRT (three-d... | 18 Years - 70 Years | Fudan University | |
| A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma | NCT04627961 | Metastatic Naso... Recurrent Nasop... | TAS-102 | 21 Years - 99 Years | National University Hospital, Singapore | |
| A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma | NCT00834093 | Nasopharyngeal ... | Epstein-Barr Vi... | 18 Years - | Dana-Farber Cancer Institute | |
| Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) | NCT03682055 | Nasopharyngeal ... Nasopharyngeal ... | VK-2019 | 18 Years - | Cullinan Therapeutics Inc. | |
| A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma | NCT04627961 | Metastatic Naso... Recurrent Nasop... | TAS-102 | 21 Years - 99 Years | National University Hospital, Singapore | |
| Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | NCT03769467 | Nasopharyngeal ... Nasopharyngeal ... Epstein-Barr Vi... Epstein-Barr Vi... Epstein-Barr Vi... | tabelecleucel pembrolizumab | 12 Years - | Atara Biotherapeutics | |
| Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal Carcinoma | NCT02610556 | Nasopharyngeal ... | Cisplatin 2 Docetaxel Cisplatin 1 Intensity-modul... | 18 Years - 65 Years | Sun Yat-sen University | |
| Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma | NCT00817258 | Nasopharyngeal ... | cisplatin 3D-CRT (three-d... | 18 Years - 70 Years | Fudan University | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage Ⅲ Nasopharyngeal Carcinoma | NCT00816855 | Nasopharyngeal ... | docetaxel, cisp... | 18 Years - 70 Years | Fudan University | |
| Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer | NCT00078494 | Nasopharyngeal ... | EBV-LMP-2 | - | National Institutes of Health Clinical Center (CC) | |
| Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) | NCT03682055 | Nasopharyngeal ... Nasopharyngeal ... | VK-2019 | 18 Years - | Cullinan Therapeutics Inc. | |
| Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients | NCT01744587 | NPC | Epigallocatechi... Placebo | 20 Years - | National Health Research Institutes, Taiwan | |
| NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer | NCT03734809 | NPC | Pembrolizumab | 18 Years - | Chinese University of Hong Kong | |
| The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT | NCT01797900 | Nasopharyngeal ... | Cisplatin Paclitaxel IMRT | 18 Years - 70 Years | ChineseAMS | |
| Prospective Nasopharyngeal Carcinoma Screening Using Plasma Epstein-Barr Virus DNA Analysis | NCT02063399 | Nasopharyngeal ... | 40 Years - 62 Years | Chinese University of Hong Kong | ||
| A Study for the Adjuvant Treatment of Breast Cancer | NCT05420467 | Breast Cancer | Docetaxel Carboplatin Trastuzumab Pertuzumab Nab paclitaxel Epirubicin Cyclophosphamid... Docetaxel Epirubicin Cyclophosphamid... Nab paclitaxel Cyclophosphamid... | 18 Years - | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Environmental and Genetic Determinants of Nasopharyngeal Carcinoma (NPC) | NCT01182909 | Nasopharyngeal ... | 18 Years - | Far Eastern Memorial Hospital | ||
| Endostar for Locally Recurrent Nasopharyngeal Carcinoma | NCT02636231 | Nasopharyngeal ... | Endostatins IMRT | 18 Years - 70 Years | Sun Yat-sen University | |
| Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients | NCT00304694 | Nasopharyngeal ... | 18 Years - 80 Years | National Taiwan University Hospital | ||
| Family Study of Head and Neck Cancers in Taiwan | NCT00342147 | Nasopharyngeal ... Herpesvirus 4, ... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Prospective Nasopharyngeal Carcinoma Screening Using Plasma Epstein-Barr Virus DNA Analysis | NCT02063399 | Nasopharyngeal ... | 40 Years - 62 Years | Chinese University of Hong Kong | ||
| Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage ⅣAB Nasopharyngeal Carcinoma | NCT00816816 | Nasopharyngeal ... | docetaxel, cisp... | 18 Years - 70 Years | Fudan University | |
| Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies | NCT04925544 | Nasopharyngeal ... Epstein-Barr Vi... | VK-2019 | 18 Years - | Stanford University | |
| A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients | NCT02578641 | Nasopharyngeal ... | autologous EBV ... combination IV ... | 18 Years - | Tessa Therapeutics | |
| Environmental and Genetic Determinants of NPC | NCT01257100 | Nasopharyngeal ... Herpesvirus 4, ... | 21 Years - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage ⅣAB Nasopharyngeal Carcinoma | NCT00816816 | Nasopharyngeal ... | docetaxel, cisp... | 18 Years - 70 Years | Fudan University | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | NCT03769467 | Nasopharyngeal ... Nasopharyngeal ... Epstein-Barr Vi... Epstein-Barr Vi... Epstein-Barr Vi... | tabelecleucel pembrolizumab | 12 Years - | Atara Biotherapeutics | |
| Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies | NCT04925544 | Nasopharyngeal ... Epstein-Barr Vi... | VK-2019 | 18 Years - | Stanford University | |
| Treatment Result of KTP Laser Nasopharyngectomy in Recurrent NPC Patients | NCT00364962 | Recurrent Nasopharyngeal ... | 20 Years - 75 Years | National Taiwan University Hospital | ||
| Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage Ⅲ Nasopharyngeal Carcinoma | NCT00816855 | Nasopharyngeal ... | docetaxel, cisp... | 18 Years - 70 Years | Fudan University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
